-transparent.png){kind=logo}
Coronary artery disease is the leading cause of death in Europe and in the US and angina is the most common symptom associated with stable coronary artery disease. Despite receiving optimal antianginal therapy, based on agents such as beta-blockers, calcium channel antagonists and nitrates, many patients continue to experience angina. Furthermore, the administration of these drugs is limited by adverse effects such as bradycardia or hypotension. Ranolazine is a new antianginal agent, recently approved as add-on therapy in patients with stable angina. This review will focus on its mechanism of action, tolerability, highlighting the clinical benefit coming from its use.
Related Publications
M Gustapane, and
M T Cardillo, and
G Biasillo, and
R Della Bona
April 2010,
Advances in therapy,
M Gustapane, and
M T Cardillo, and
G Biasillo, and
R Della Bona
December 2009,
Ugeskrift for laeger,
M Gustapane, and
M T Cardillo, and
G Biasillo, and
R Della Bona
October 2008,
Lancet (London, England),
M Gustapane, and
M T Cardillo, and
G Biasillo, and
R Della Bona
June 2007,
Issues in emerging health technologies,
M Gustapane, and
M T Cardillo, and
G Biasillo, and
R Della Bona
December 2006,
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
M Gustapane, and
M T Cardillo, and
G Biasillo, and
R Della Bona
January 2001,
Heart disease (Hagerstown, Md.),
M Gustapane, and
M T Cardillo, and
G Biasillo, and
R Della Bona
January 2005,
Cardiology in review,
M Gustapane, and
M T Cardillo, and
G Biasillo, and
R Della Bona
January 2008,
Vascular health and risk management,
M Gustapane, and
M T Cardillo, and
G Biasillo, and
R Della Bona
January 2006,
American journal of cardiovascular drugs : drugs, devices, and other interventions,
M Gustapane, and
M T Cardillo, and
G Biasillo, and
R Della Bona
January 2006,
Pharmacotherapy,
